<- Go Home

hVIVO plc

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Market Cap

GBP 73.1M

Volume

3.2M

Cash and Equivalents

GBP 44.2M

EBITDA

GBP 14.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

GBP 16.4M

Profit Margin

24.79%

52 Week High

GBP 0.31

52 Week Low

GBP 0.07

Dividend

1.86%

Price / Book Value

1.64

Price / Earnings

6.94

Price / Tangible Book Value

1.88

Enterprise Value

GBP 41.9M

Enterprise Value / EBITDA

2.56

Operating Income

GBP 12.9M

Return on Equity

26.97%

Return on Assets

9.34

Cash and Short Term Investments

GBP 44.2M

Debt

GBP 12.9M

Equity

GBP 44.7M

Revenue

GBP 66.2M

Unlevered FCF

GBP 3.5M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches